MTOR and Adenoma sebaceum: While the evidence and consensus recommendations suggest the use of topical mTOR inhibitors for the management of facial angiofibroma [3], lack of FDA-approved topical therapy at the time of this study meant there was no standardized formulation available, and many individuals did not have access to topical mTOR inhibitor therapy in the US.